The Study Of Contrast-enhanced Ultrasound And Detection Of Human Mammaglobin Gene Of Axilla Lymph Node Of Breast Masses

Objective To evaluate the clinical value of SonoVue in sentinel lymphatic node (SLN) of patients with breast masses by analyzing the enhanced phase of axillary lymph node (ALN) after subcutaneous injection SonoVue and detecting the expression of human mammaglobin (hMAM) in ALN of human breast masses.Methods 21 cases with breast masses were injected subcutaneously with contrast agent and Methylene blue successively to the same position of borderline of breast tumor. The enhanced phases of ipsilateral ALN were observed. The all SLNs were marked preoperatively and were examined with routine pathological and hMAMmRNA of reverse transcription- polymerase chain reaction (RT-PCR) test postoperatively.Results 15 patients were detected SLN after angiography, the detection rate was 71.4% (15/21), 19 cases after methylene blue, the detection rate was 90.5% (19/21); Accurate diagnosis: angiography is 15 cases, methylene blue is 17 cases, no difference between the two groups in statistical significance; 49 SLNs were detected (benign was 11; malignant was 38 ), pathology showed that 26 was transfered, the accuracy was 75.5% (37/49), RT-PCR showed 37 was positive, the accuracy was 97.9% ( 48/49), there was a significant difference between the two results in statistics.Conclusions The subcutaneous injection SonoVue is effective to detect SLN in patients with breast cancer and predict benign or malignant; RT-PCR for hMAMmRNA test could significantly increase the detection rate of metastasis SLN with breast cancer.